Malignant Mesothelioma Pipeline Review, H2 2018 - ResearchAndMarkets.com
The "Malignant Mesothelioma - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Malignant Mesothelioma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 35, 33, 17, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 5, 5 and 8 molecules, respectively.
Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Malignant Mesothelioma - Overview
- Malignant Mesothelioma - Therapeutics Development
- Malignant Mesothelioma - Therapeutics Assessment
- Malignant Mesothelioma - Companies Involved in Therapeutics Development
- Malignant Mesothelioma - Drug Profiles
- Malignant Mesothelioma - Dormant Projects
- Malignant Mesothelioma - Discontinued Products
- Malignant Mesothelioma - Product Development Milestones
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mp6h73/malignant?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181012005110/en/